23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan).
The assessment applies to Trodelvy as the sole treatment of adult patients with non-resectable or disseminated, triple negative breast cancer who have previously received two or more systemic treatments, at least one of them for advanced disease.